Recent Advances in Gene Therapy for Hemophilia

Area of Science:

• * Genetics and Molecular Biology
• * Hematology
• * Gene Therapy

Background:

• * Hemophilia is an X-linked monogenic disorder caused by mutations in F8 or F9 genes, leading to clotting factor deficiencies.
• * Clinical manifestations include spontaneous hemorrhages, with severe cases risking stroke and arthropathy, impacting quality of life.
• * Its monogenic nature and predictable outcomes make hemophilia a prime target for gene therapy.

Purpose of the Study:

• * To provide a comprehensive review of recent advances in hemophilia gene therapy.
• * To focus on clinical translation and technological innovations in the field.
• * To highlight strategies for overcoming existing barriers and enhancing treatment accessibility.

Main Methods:

• * Review of current Food and Drug Administration (FDA)-approved gene therapies utilizing recombinant adeno-associated virus (AAV) vectors.
• * Analysis of AAV vector delivery of functional transgene cassettes to hepatocytes.
• * Examination of sustained clotting factor activity and patient outcomes.

Main Results:

• * FDA-approved AAV-based gene therapies provide sustained Factor VIII (FVIII) and Factor IX (FIX) activity after a single dose.
• * These therapies demonstrate robust hemostatic control and significant improvements in patients' quality of life.
• * Challenges persist, including immunogenicity, thrombotic risks, potential gene integration, and high costs.

Conclusions:

• * Hemophilia gene therapy shows significant promise for sustained treatment and improved quality of life.
• * Future research must address limitations such as patient eligibility, cost, and safety concerns.
• * Integrating precision gene-editing technologies is crucial for advancing hemophilia cure potential.